$46.76▾ 0.32%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$19.91MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+32.4%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Supernus Pharmaceuticals, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is growing strongly year over year.
Key numbers
Valuation
EPS (TTM)$-1.92
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-13.2%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$830.44M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days2 articles
0 bullish1 neutral1 bearish
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.